cd4^lvfoxp3
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 22, 2022 (NCT05241444)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetImmunity, desensitized
immunity, desensitized
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05241444 | Phase 1 | Mar 22, 2022 | California Institute for Regenerative Medicine (CIRM), Stanford University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1